Clinical toxicities of nanocarrier systems.

Vega-Villa, Karina R.; Takemoto, Jody K.; Yáñez, Jaime A.; Remsberg, Connie M.; Forrest, M. Laird; Davies, Neal M.

doi:10.1016/j.addr.2007.11.007

Cited by 325Nanoparticle-Based Drug DeliveryNanoparticles: synthesis and applicationsImmunotoxicology and immune responses

Clinical toxicities of nanocarrier systems.

Vega-Villa, Karina R., Takemoto, Jody K., Yáñez, Jaime A., Remsberg, Connie M., Forrest, M. Laird, Davies, Neal M.·2008·Advanced Drug Delivery Reviews

DOI 10.1016/j.addr.2007.11.007

Open this paper in CoChat — free account

Abstract

Toxicity of nanocarrier systems involves physiological, physicochemical, and molecular considerations. Nanoparticle exposures through the skin, the respiratory tract, the gastrointestinal tract and the lymphatics have been described. Nanocarrier systems may induce cytotoxicity and/or genotoxicity, whereas their antigenicity is still not well understood. Nanocarrier may alter the physicochemical properties of xenobiotics resulting in pharmaceutical changes in stability, solubility, and pharmacokinetic disposition. In particular, nanocarriers may reduce toxicity of hydrophobic cancer drugs that are solubilized. Nano regulation is still undergoing major changes to encompass environmental, health, and safety issues. The rapid commercialization of nanotechnology requires thoughtful environmental, health and safety research, meaningful, and an open discussion of broader societal impacts, and urgent toxicological oversight action.

Integrity signals

Registry

Crossref · 10.1016/j.addr.2007.11.007

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Toxicity pattern of nanocarriers depends on their state of aggregation, mechanical properties, and mode of drug administration.
“Toxicity pattern of the nanocarriers depends on its state of aggregation, mechanical properties, mode of drug administration (Vega-Villa et al., 2008).”
From Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs (2020) · cites this paper as Vega-Villa et al., 2008

Toxic potential of materials at the nanolevel
Nel, A., Xia, T., Mädler, L., & Li, N. (2006) · Science · doi:10.1126/science.1114397 · Cited by 9,324 · see citing works
Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles
Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7339 · Cited by 7,891 · see citing works
Quantum Dots for Live Cells, in Vivo Imaging, and Diagnostics
Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., Sundaresan, G., Wu, A. M., Gambhir, S. S., & Weiss, S. (2005) · Science · doi:10.1126/science.1104274 · Cited by 7,794 · see citing works
Translocation of inhaled ultrafine particles to the brain
Oberdörster, G., Sharp, Z., Atudorei, V., Elder, A., Gelein, R., Kreyling, W., & Cox, C. (2004) · Inhalation Toxicology · doi:10.1080/08958370490439597 · Cited by 2,606 · see citing works
The potential environmental impact of engineered nanomaterials
Colvin, V. L. (2003) · Nature Biotechnology · doi:10.1038/nbt875 · Cited by 2,161 · see citing works
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029 · see citing works
Dendrimers in biomedical applications—reflections on the field
Svenson, S., & Tomalia, D. A. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.09.018 · Cited by 1,925 · see citing works
Nanotech approaches to drug delivery and imaging
Sahoo, S. K., & Labhasetwar, V. D. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02903-9 · Cited by 1,208 · see citing works
EXTRAPULMONARY TRANSLOCATION OF ULTRAFINE CARBON PARTICLES FOLLOWING WHOLE-BODY INHALATION EXPOSURE OF RATS
Oberdörster, G., Sharp, Z. D., Atudorei, V. N., Elder, A. C. P., Gelein, R. M., Lunts, A., Kreyling, W. G., & Cox, C. (2002) · Journal of Toxicology and Environmental Health · doi:10.1080/00984100290071658 · Cited by 1,081 · see citing works
Acute toxicological effects of copper nanoparticles in vivo
Chen, Z., Meng, H., Xing, G., Chen, C., Zhao, Y., Jia, G., Wang, T., Yuan, H. Y., Ye, C., Zhao, F., et al. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2005.10.003 · Cited by 965 · see citing works
Carbon nanotubes as nanomedicines: From toxicology to pharmacology☆
Lacerda, L., Bianco, A., Prato, M., & Kostarelos, K. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.015 · Cited by 839 · see citing works
Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles
Müller, R. H., & Keck, C. M. (2004) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2004.06.007 · Cited by 822 · see citing works
Assessing Toxicity of Fine and Nanoparticles: Comparing In Vitro Measurements to In Vivo Pulmonary Toxicity Profiles
Sayes, C. M., Reed, K. L., & Warheit, D. B. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm018 · Cited by 765 · see citing works
Nanoparticles: pharmacological and toxicological significance
Medina, C., Santos-Martínez, M. J., Radomski, A. D., Corrigan, O. I., & Radomski, M. W. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707130 · Cited by 741 · see citing works
Liposome application: problems and prospects.
Barenholz, Y. (2001) · Current Opinion in Colloid & Interface Science · doi:10.1016/s1359-0294(00)00090-x · Cited by 659 · see citing works
Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: Differential responses related to surface properties
Warheit, D. B., Webb, T. R., Reed, K. L., Frerichs, S., & Sayes, C. M. (2006) · Toxicology · doi:10.1016/j.tox.2006.11.002 · Cited by 645 · see citing works
Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin
Matsumura, Y., Hamaguchi, T., Ura, T., Muro, K., Yamada, Y., Shimada, Y., Shirao, K., Okusaka, T., Ueno, H., Ikeda, M., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602204 · Cited by 623 · see citing works
Nanotoxicity of iron oxide nanoparticle internalization in growing neurons
Pisanic, T. R., Blackwell, J. D., Shubayev, V. I., Fiñones, R. R., & Jin, S. (2007) · Biomaterials · doi:10.1016/j.biomaterials.2007.01.043 · Cited by 585 · see citing works
Nanoparticles: Health Effects—Pros and Cons
Gwinn, M. R., & Vallyathan, V. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.8871 · Cited by 570 · see citing works
Penetration of Intact Skin by Quantum Dots with Diverse Physicochemical Properties
Ryman-Rasmussen, J. P., Riviere, J. E., & Monteiro-Riviere, N. A. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfj122 · Cited by 535 · see citing works
Microparticles and nanoparticles for drug delivery
Kohane, D. S. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.21301 · Cited by 517 · see citing works
Skin as a route of exposure and sensitization in chronic beryllium disease.
Tinkle, S. S., Antonini, J. M., Rich, B. A., Roberts, J. R., Salmen, R., Depree, K. M., & Adkins, E. J. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.5999 · Cited by 483 · see citing works
What do we (need to) know about the kinetic properties of nanoparticles in the body?
Hagens, W. I., Oomen, A. G., de Jong, W. H., Cassee, F. R., & Sips, A. J. A. M. (2007) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2007.07.006 · Cited by 464 · see citing works
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 450 · see citing works
Biomedical Applications and Potential Health Risks of Nanomaterials: Molecular Mechanisms
Lanone, S., & Boczkowski, J. (2006) · Current Molecular Medicine · doi:10.2174/156652406778195026 · Cited by 436 · see citing works
Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats
Fabian, E. J., Landsiedel, R., Ma‐Hock, L., Wiench, K., Wohlleben, W., & van Ravenzwaay, B. (2007) · Archives of Toxicology · doi:10.1007/s00204-007-0253-y · Cited by 398 · see citing works
Pluronic® block copolymers: novel functional molecules for gene therapy
Kabanov, A. V., Lemieux, P., Vinogradov, S. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00018-2 · Cited by 376 · see citing works
Nanomedicines and nanotoxicology: some physiological principles
Garnett, M. C., & Kallinteri, P. (2006) · Occupational Medicine · doi:10.1093/occmed/kql052 · Cited by 352 · see citing works
Effects of Mechanical Flexion on the Penetration of Fullerene Amino Acid-Derivatized Peptide Nanoparticles through Skin
Rouse, J. G., Yang, J., Ryman-Rasmussen, J. P., Barron, A. R., & Monteiro-Riviere, N. A. (2006) · Nano Letters · doi:10.1021/nl062464m · Cited by 317 · see citing works
Pulmonary Bioassay Studies with Nanoscale and Fine-Quartz Particles in Rats: Toxicity is Not Dependent upon Particle Size but on Surface Characteristics
Warheit, D. B., Webb, T. R., Colvin, V. L., Reed, K. L., & Sayes, C. M. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl128 · Cited by 297 · see citing works
Liposomal Drug Formulations
Allen, T. M. (1998) · Drugs · doi:10.2165/00003495-199856050-00001 · Cited by 285 · see citing works
Nanotechnology Grows Up
Service, R. F. (2004) · Science · doi:10.1126/science.304.5678.1732 · Cited by 285 · see citing works
A new approach to the toxicity testing of carbon-based nanomaterials—The clonogenic assay
Herzog, E., Casey, A., Lyng, F. M., Chambers, G., Byrne, H. J., & Davoren, M. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2007.08.009 · Cited by 263 · see citing works
Colloidal Stabilization of Nanoparticles in Concentrated Suspensions
Studart, A. R., Amstad, E., & Gauckler, L. J. (2006) · Langmuir · doi:10.1021/la062042s · Cited by 261 · see citing works
Nanomedicine and nanotoxicology: two sides of the same coin
Kagan, V. E., Bayır, H., & Shvedova, A. A. (2005) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2005.10.003 · Cited by 245 · see citing works
Cytotoxicity of water-soluble fullerene in vascular endothelial cells
Yamawaki, H., & Iwai, N. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00481.2005 · Cited by 243 · see citing works
Ostwald Ripening of β -Carotene Nanoparticles
Liu, Y., Kathan, K., Saad, W., et al. (2007) · Physical Review Letters · doi:10.1103/physrevlett.98.036102 · Cited by 219 · see citing works
Polymer genomics: An insight into pharmacology and toxicology of nanomedicines☆
Kabanov, A. V. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.019 · Cited by 204 · see citing works
PLGA nanoparticles for oral delivery of cyclosporine: Nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral®
Italia, J. L., Bhatt, D. K., Bhardwaj, V., Tikoo, K., & Kumar, M. N. V. R. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.02.004 · Cited by 203 · see citing works
Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics
Hawley, A. E., Davis, S. S., & Illum, L. (1995) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00045-9 · Cited by 183 · see citing works
In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles
Forrest, M. L., Won, C.-Y., Malick, A. W., & Kwon, G. S. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.10.008 · Cited by 175 · see citing works
Self-citation
Smaller is not always better: nanotechnology yields nanotoxicology
Kipen, H. M., & Laskin, D. L. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00277.2005 · Cited by 161 · see citing works
Solution Structures and Integrin Binding Activities of an RGD Peptide with Two Isomers
Assa‐Munt, N., Jia, X., Laakkonen, P. M., & Ruoslahti, E. I. (2001) · Biochemistry · doi:10.1021/bi002101f · Cited by 157 · see citing works
Cellular Interaction of Different Forms of Aluminum Nanoparticles in Rat Alveolar Macrophages
Wagner, A. J., Bleckmann, C. A., Murdock, R. C., Schrand, A. M., Schlager, J. J., & Hussain, S. M. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp068938n · Cited by 154 · see citing works
Slow intracellular trafficking of catalase nanoparticles targeted to ICAM-1 protects endothelial cells from oxidative stress
Muro, S., Cui, X., Gajewski, C., et al. (2003) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00099.2003 · Cited by 153 · see citing works
COMBUSTION‐DERIVED NANOPARTICLES: MECHANISMS OF PULMONARY TOXICITY
BéruBé, K., Balharry, D., Sexton, K., et al. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04733.x · Cited by 141 · see citing works
Nanomedicine: An unresolved regulatory issue
Chan, V. S. W. (2006) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2006.04.009 · Cited by 138 · see citing works
Development of Biodegradable Nanoparticles for Oral Delivery of Ellagic Acid and Evaluation of Their Antioxidant Efficacy Against Cyclosporine A-Induced Nephrotoxicity in Rats
Sonaje, K., Italia, J. L., Sharma, G., Bhardwaj, V., Tikoo, K., & Kumar, M. N. V. R. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9207-y · Cited by 136 · see citing works
Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography
Moghimi, S. M. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00099-4 · Cited by 135 · see citing works
Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution
Montazeri Aliabadi, H., Brocks, D. R., & Lavasanifar, A. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2005.05.042 · Cited by 132 · see citing works
Multi-walled carbon nanotube exposure alters protein expression in human keratinocytes
Witzmann, F. A., & Monteiro‐Riviere, N. A. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2006.07.005 · Cited by 127 · see citing works
5-amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease
Pertuit, D., Moulari, B., Betz, T., Nadaradjane, A., Neumann, D., Ismaïli, L., Refouvelet, B., Pellequer, Y., & Lamprecht, A. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.008 · Cited by 126 · see citing works
Nanotechnology and Nanotoxicology
Curtis, J. A., Greenberg, M., Kester, J. E., Phillips, S., & Krieger, G. R. (2006) · Toxicological Reviews · doi:10.2165/00139709-200625040-00005 · Cited by 124 · see citing works
In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: The magnetic bio-nanoparticles as drug carriers
Sun, J., Duan, J., Dai, S., et al. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.08.018 · Cited by 121 · see citing works
Oral vaccine delivery
Russell-Jones, G. J. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00231-x · Cited by 103 · see citing works
Nanoparticles-A Thoracic Toxicology Perspective
Duffin, R., Mills, N. L., & Donaldson, K. (2007) · Yonsei Medical Journal · doi:10.3349/ymj.2007.48.4.561 · Cited by 98 · see citing works
Topical non-invasive gene delivery using gemini nanoparticles in interferon-γ-deficient mice
Badea, I., Wettig, S. D., Verrall, R. E., et al. (2007) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2007.01.002 · Cited by 89 · see citing works
Surface‐Functionalized Nanoparticle Library Yields Probes for Apoptotic Cells
Schellenberger, E. A., Reynolds, F., Weissleder, R., & Josephson, L. (2004) · ChemBioChem · doi:10.1002/cbic.200300713 · Cited by 86 · see citing works
Cardiotoxicity reduction induced by halofantrine entrapped in nanocapsule devices
Leite, E. A., Grabe‐Guimarães, A., Guimarães, H. N., et al. (2007) · Life Sciences · doi:10.1016/j.lfs.2006.12.019 · Cited by 82 · see citing works
Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model
Alves‐Rosa, F., Stanganelli, C., Cabrera, J., van Rooijen, N., Palermo, M. S., & Isturiz, M. A. (2000) · Blood · doi:10.1182/blood.v96.8.2834 · Cited by 74 · see citing works
Systemic Depletion of Macrophages by Liposomal Bisphosphonates Reduces Neointimal Formation Following Balloon-Injury in the Rat Carotid Artery
Danenberg, H. D., Fishbein, I., Epstein, H., et al. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200311000-00014 · Cited by 71 · see citing works
Effects of inhaled nanoparticles on acute lung injury induced by lipopolysaccharide in mice
Inoue, K.-I., Takano, H., Yanagisawa, R., et al. (2007) · Toxicology · doi:10.1016/j.tox.2007.05.022 · Cited by 69 · see citing works
Lipid-based formulations of amphotericin B
Veerareddy, P. R., & Vobalaboina, V. (2004) · Drugs of today · doi:10.1358/dot.2004.40.2.799425 · Cited by 68 · see citing works
Role of biokinetics in risk assessment of drugs and chemicals in children
de Zwart, L. L., Haenen, H. E. M. G., Versantvoort, C. H. M., Wolterink, G., van Engelen, J. G. M., & Sips, A. J. A. M. (2004) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2004.02.006 · Cited by 63 · see citing works
Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin
Yáñez, J. A., Forrest, M. L., Ohgami, Y., Kwon, G. S., & Davies, N. M. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0458-z · Cited by 63 · see citing works
Self-citation
Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly (ethylene glycol)-b-poly (ε-caprolactone) micelles
Forrest, M. L., Zhao, A., Won, C.-Y., Malick, A. W., & Kwon, G. S. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.07.003 · Cited by 59 · see citing works
Self-citation
In vivo toxic studies and biodistribution of near infrared sensitive Au–Au2S nanoparticles as potential drug delivery carriers
Huang, X., Zhang, B., Ren, L., et al. (2007) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-007-3210-7 · Cited by 55 · see citing works
Beyond biotechnology: FDA regulation of nanomedicine.
Miller, J. M. (2003) · PubMed · Cited by 53 · see citing works
Toxicology as a nanoscience? – Disciplinary identities reconsidered
Kurath, M., & Maasen, S. (2006) · Particle and Fibre Toxicology · doi:10.1186/1743-8977-3-6 · Cited by 48 · see citing works
Surface-modified nanocrystalline ceramics for drug delivery applications
Kossovsky, N., Gelman, A., Sponsler, E., Hnatyszyn, H. J., Rajguru, S., Torres, M., Pham, M., Crowder, J., Zemanovich, J., Chung, A., et al. (1994) · Biomaterials · doi:10.1016/0142-9612(94)90270-4 · Cited by 44 · see citing works
Long-term shelf stability of amphiphilicβ-cyclodextrin nanosphere suspensions monitored by dynamic light scattering and cryo-transmission electron microscopy
Gèze, A., Putaux, J., Choisnard, L., et al. (2004) · Journal of Microencapsulation · doi:10.1080/02652040400008457 · Cited by 42 · see citing works
Recombinant polymers for cancer gene therapy: A minireview
Haider, M. A., Hatefi, A., & Ghandehari, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.09.018 · Cited by 34 · see citing works
The Cytotoxicity of Metal‐Encapsulating Carbon Nanocapsules
Uo, M., Tamura, K., Sato, Y., et al. (2005) · Small · doi:10.1002/smll.200400143 · Cited by 34 · see citing works
Is Nanotechnology Ready for Primetime?
Brower, V. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj028 · Cited by 29 · see citing works
Nanoparticle Multilayers: Surface Modification of Photosensitive Drug Microparticles for Increased Stability and In Vitro Bioavailability
Li, N., Kommireddy, D. S., LVOV, Y. M., et al. (2006) · Journal of Nanoscience and Nanotechnology · doi:10.1166/jnn.2006.421 · Cited by 23 · see citing works
THE PERMEABILITY OF THE BASAL LAMINA AT THE NEUROMUSCULAR JUNCTION. AN ULTRASTRUCTURAL STUDY OF RAT SKELETAL MUSCLE USING PARTICULATE TRACERS
Oldfors, A., & Fardeau, M. (1983) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1983.tb00127.x · Cited by 19 · see citing works
In vivo toxicity of nanoparticles for gene therapy in the eye
Lutty, G. A., Kim, S., Bhutto, I. A., et al. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2006.10.110 · Cited by 3 · see citing works
Toxicologic considerations of polymer nanoparticles: the rules of toxicity still apply
Schneider, R. J. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2006.10.113 · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

The progress of silver nanoparticles in the antibacterial mechanism, clinical application and cytotoxicity
You, C., Han, C., Wang, X., Zheng, Y., Li, Q., Hu, X., & Sun, H. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1792-8 · Cited by 447 · see citing works
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305 · see citing works
Nanomicelles: types, properties and applications in drug delivery
Bose, A., Roy Burman, D., Sikdar, B., & Patra, P. (2021) · IET Nanobiotechnology · doi:10.1049/nbt2.12018 · Cited by 278 · see citing works
Nanotechnology—novel therapeutics for CNS disorders
Srikanth, M., & Kessler, J. A. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.76 · Cited by 198 · see citing works
Mannan-Modified Solid Lipid Nanoparticles for Targeted Gene Delivery to Alveolar Macrophages
Yu, W., Liu, C., Liu, Y., Zhang, N., & Xu, W. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0149-z · Cited by 137 · see citing works

The emergence of nanocarriers in the management of diseases and disorders
Khulbe, P., Singh, D., Aman, A., et al. (2023) · Community Acquired Infection · doi:10.54844/cai.2022.0139 · Cited by 5 · see citing works
Delivery of Doxorubicin Using Double-Layered Core–Shell Nanocarrier Based on Magnetic Fe 3 O 4 Core and Salep Shells
Hosseini, S. H., Alipour, S., & Zohreh, N. (2018) · Langmuir · doi:10.1021/acs.langmuir.8b02390 · Cited by 20 · see citing works
Strategies for ligand-installed nanocarriers
Miyazaki, T., Nakagawa, Y., & Cabral, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821506-7.00024-7 · Cited by 3 · see citing works
General justification in terms of effectiveness and toxicities for the use of nanocarriers
Handali, S., & Rezaei, M. (2023) · Journal of Nanoparticle Research · doi:10.1007/s11051-023-05826-y · Cited by 3 · see citing works
An Analysis of the Capturing and Passing Ability of a DNA Origami Nanocarrier with the Aid of Molecular Dynamics Simulation
Mogheiseh, M., & Ghasemi, R. H. (2022) · Molecular Biotechnology · doi:10.1007/s12033-022-00636-4 · Cited by 8 · see citing works

Authors: Vega-Villa, K. R., Takemoto, J. K., Yáñez, J. A., Remsberg, C. M., Forrest, M. L., & Davies, N. M.
Affiliations: Washington State University (US)
University of Kansas (US)
Corresponding author: Davies, Neal M.
ORCID: Takemoto, Jody K.
Yáñez, Jaime A.
Remsberg, Connie M.
Forrest, M. Laird
Davies, Neal M.
Venue: Advanced Drug Delivery Reviews
Publisher: Elsevier BV
Published: 2008-05
Volume: 60
Issue: 8
Pages: 929-938
ISSN: 0169-409X (ISSN-L)
DOI: 10.1016/j.addr.2007.11.007
OpenAlex: W2003699527
Cited by: 325
References: 78
Citations by year: 2026: 9 · 2025: 15 · 2024: 18 · 2023: 18 · 2022: 24 · 2021: 22 · 2020: 24 · 2019: 17 · 2018: 22 · 2017: 14 · 2016: 10 · 2015: 9 · 2014: 20 · 2013: 25 · 2012: 15
FWCI: 0.98
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Advanced Drug Delivery Reviews (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5p20rr015563-08)
National Cancer Institute (R21CA132033)
National Center for Research Resources (P20-RR015563)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Physical Sciences › Materials Science › Materials Chemistry › Nanoparticles: synthesis and applications
Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
Keywords: nanocarrier toxicity, nanoparticles, cytotoxicity, genotoxicity, drug solubilization, hydrophobic anticancer drugs, pharmacokinetics, nanotoxicology, nanotechnology safety
MeSH terms: Drug Carriers, Pharmaceutical Preparations, Humans, Mutagens, Tissue Distribution, Drug Delivery Systems, Nanoparticles, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical toxicities of nanocarrier systems.

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks